US Congress Warns Small Investment Banks on IPO Responsibilities
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 13 2026
0mins
Should l Buy POM?
Source: Benzinga
- Congressional Warning: A U.S. congressional committee has issued warnings to three small investment banks regarding their potential involvement in underwriting suspicious Chinese IPOs, indicating a growing hostility on Wall Street towards Chinese firms.
- Declining IPOs: The tightening scrutiny on Chinese companies has led to a rapid decline in new IPOs, reflecting U.S. concerns about preventing American funds from being used for defense-related activities by these firms.
- Fraud Patterns Exposed: Since 2023, Chinese companies employing 'pump-and-dump' schemes have reportedly caused $16 billion in losses for American investors, with about a quarter of smaller Chinese listings showing signs of fraud, exacerbating market distrust.
- Regulatory Strengthening: The CSRC has intensified its approval process for companies seeking to list abroad, with evidence of increased scrutiny on suspicious applications, highlighting a joint effort by both the U.S. and China to combat market manipulation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy POM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on POM
About POM
PomDoctor Ltd is a holding company principally engaged in operating a online medical services platform for chronic diseases. The Company operates its businesses through two segments. The Internet Hospital segment mainly engaged in providing online follow-up consultations and online prescription renewal service to customers and also sells prescription to customers through the website and apps. The Pharmaceutical Supply Chain segment mainly engaged in pharmacy retail sales and wholesale. The Company mainly operates its businesses in the domestic market.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Reminder for PomDoctor Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased PomDoctor securities between October 9, 2025, and December 11, 2025, to apply as lead plaintiffs by April 7, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Participants can obtain compensation without any upfront costs through a contingency fee arrangement, reducing the financial burden on investors and encouraging more victims to join the lawsuit.
- Lawsuit Background: The lawsuit alleges that PomDoctor made false and misleading statements during the class period, involving fraudulent stock promotions and insider selling, which resulted in investor losses and damaged the company's reputation.
- Law Firm Advantage: Rosen Law Firm is renowned for its successful track record in securities class actions, having secured hundreds of millions in settlements, and choosing this firm increases the likelihood of a favorable outcome for investors, ensuring their rights are effectively protected.
See More
PomDoctor Faces Class Action Lawsuit; Investors Encouraged to Contact Attorneys
- Class Action Filed: Bragar Eagel & Squire has initiated a class action lawsuit against PomDoctor in the Southern District of New York on behalf of investors who purchased securities between October 9 and December 11, 2025, indicating significant legal challenges for the company.
- Allegations of Misrepresentation: The lawsuit alleges that PomDoctor failed to disclose critical adverse facts regarding its business and trading activities during the class period, misleading investors and negatively impacting the company's reputation and stock price.
- Insider Trading Claims: The complaint highlights that insiders allegedly used offshore accounts to facilitate stock dumping amid a fraudulent stock promotion scheme involving misinformation on social media, exacerbating investor losses and revealing serious governance issues within the company.
- Investor Rights Protection: Investors are urged to apply by April 7, 2026, to be appointed as lead plaintiffs, with Bragar Eagel & Squire offering no-cost legal consultations to safeguard investors' rights and interests.
See More
Investigation into Pomdoctor Securities Litigation Announced
- Legal Investigation: Faruq & Faruq, LLP is investigating potential claims against Pomdoctor Limited, specifically urging investors who purchased securities between October 9, 2025, and December 11, 2025, to apply for lead plaintiff status in a federal securities class action by the April 13, 2026 deadline.
- Stock Price Plunge: Pomdoctor's stock price fell from approximately $0.50 on December 10, 2025, to about $0.38 the following day, representing a decline of roughly $0.12 or 24% in a single trading session, reflecting widespread investor concerns regarding the company's financial performance and valuation.
- False Promotion Allegations: The complaint alleges that Pomdoctor and its executives violated federal securities laws by making false and misleading statements and failing to disclose fraudulent stock promotion schemes involving social media misinformation, leading to investor misconceptions about the company's prospects.
- Investor Rights Protection: Faruq & Faruq encourages anyone with information regarding Pomdoctor's conduct, including whistleblowers and former employees, to contact the firm directly to provide information for potential legal actions, ensuring the protection of investor rights.
See More
Pomdoctor Investors Encouraged to Seek Legal Options
- Legal Investigation Initiated: Faruq & Faruqi LLP is investigating potential claims against Pomdoctor, particularly for investors who purchased securities between October 9, 2025, and December 11, 2025, aiming to protect investors' legal rights.
- Claim Deadline Reminder: Investors should note that the deadline to seek the role of lead plaintiff in the federal securities class action is April 13, 2026, making this time frame critical for asserting their claims.
- Direct Contact Encouragement: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing multiple contact numbers to facilitate consultations, demonstrating the firm's commitment to client support.
- Potential Impact Assessment: This investigation could negatively affect Pomdoctor's stock price and market confidence, prompting investors to stay informed about their legal options to take action if necessary.
See More
PomDoctor Securities Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased PomDoctor Ltd. (NASDAQ: POM) securities between October 9 and December 11, 2025, to apply as lead plaintiffs by April 7, 2026, to potentially receive compensation without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that during the class period, PomDoctor was involved in a fraudulent stock promotion scheme that misled investors through social media misinformation and insider trading, which inflated stock prices and misrepresented the company's operations.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, recovering over $438 million for investors in 2019 alone, highlighting its strong track record in this legal domain.
- Investor Guidance: Investors are advised to carefully select legal counsel, with Rosen Law Firm recommending attorneys with proven success in class actions to ensure effective representation in the litigation process.
See More
Reminder for PomDoctor Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased PomDoctor Ltd. (NASDAQ:POM) securities between October 9 and December 11, 2025, to apply as lead plaintiffs by April 7, 2026, or risk losing the opportunity to represent other investors.
- Fee Arrangement: Investors joining the PomDoctor class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages broader participation in the lawsuit.
- Lawsuit Background: The lawsuit alleges that PomDoctor was involved in a fraudulent stock promotion scheme during the class period, with insiders using offshore accounts to dump shares, misleading investors and impacting the company's stock price performance.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, demonstrating its expertise and success rate, which investors should consider when selecting legal counsel.
See More
Reminder for PomDoctor Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased PomDoctor securities between October 9, 2025, and December 11, 2025, to apply as lead plaintiffs by April 7, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Participants can obtain compensation without any upfront costs through a contingency fee arrangement, reducing the financial burden on investors and encouraging more victims to join the lawsuit.
- Lawsuit Background: The lawsuit alleges that PomDoctor made false and misleading statements during the class period, involving fraudulent stock promotions and insider selling, which resulted in investor losses and damaged the company's reputation.
- Law Firm Advantage: Rosen Law Firm is renowned for its successful track record in securities class actions, having secured hundreds of millions in settlements, and choosing this firm increases the likelihood of a favorable outcome for investors, ensuring their rights are effectively protected.
See More
PomDoctor Faces Class Action Lawsuit; Investors Encouraged to Contact Attorneys
- Class Action Filed: Bragar Eagel & Squire has initiated a class action lawsuit against PomDoctor in the Southern District of New York on behalf of investors who purchased securities between October 9 and December 11, 2025, indicating significant legal challenges for the company.
- Allegations of Misrepresentation: The lawsuit alleges that PomDoctor failed to disclose critical adverse facts regarding its business and trading activities during the class period, misleading investors and negatively impacting the company's reputation and stock price.
- Insider Trading Claims: The complaint highlights that insiders allegedly used offshore accounts to facilitate stock dumping amid a fraudulent stock promotion scheme involving misinformation on social media, exacerbating investor losses and revealing serious governance issues within the company.
- Investor Rights Protection: Investors are urged to apply by April 7, 2026, to be appointed as lead plaintiffs, with Bragar Eagel & Squire offering no-cost legal consultations to safeguard investors' rights and interests.
See More
Investigation into Pomdoctor Securities Litigation Announced
- Legal Investigation: Faruq & Faruq, LLP is investigating potential claims against Pomdoctor Limited, specifically urging investors who purchased securities between October 9, 2025, and December 11, 2025, to apply for lead plaintiff status in a federal securities class action by the April 13, 2026 deadline.
- Stock Price Plunge: Pomdoctor's stock price fell from approximately $0.50 on December 10, 2025, to about $0.38 the following day, representing a decline of roughly $0.12 or 24% in a single trading session, reflecting widespread investor concerns regarding the company's financial performance and valuation.
- False Promotion Allegations: The complaint alleges that Pomdoctor and its executives violated federal securities laws by making false and misleading statements and failing to disclose fraudulent stock promotion schemes involving social media misinformation, leading to investor misconceptions about the company's prospects.
- Investor Rights Protection: Faruq & Faruq encourages anyone with information regarding Pomdoctor's conduct, including whistleblowers and former employees, to contact the firm directly to provide information for potential legal actions, ensuring the protection of investor rights.
See More
Pomdoctor Investors Encouraged to Seek Legal Options
- Legal Investigation Initiated: Faruq & Faruqi LLP is investigating potential claims against Pomdoctor, particularly for investors who purchased securities between October 9, 2025, and December 11, 2025, aiming to protect investors' legal rights.
- Claim Deadline Reminder: Investors should note that the deadline to seek the role of lead plaintiff in the federal securities class action is April 13, 2026, making this time frame critical for asserting their claims.
- Direct Contact Encouragement: Securities Litigation Partner Josh Wilson encourages affected investors to reach out directly, providing multiple contact numbers to facilitate consultations, demonstrating the firm's commitment to client support.
- Potential Impact Assessment: This investigation could negatively affect Pomdoctor's stock price and market confidence, prompting investors to stay informed about their legal options to take action if necessary.
See More
PomDoctor Securities Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased PomDoctor Ltd. (NASDAQ: POM) securities between October 9 and December 11, 2025, to apply as lead plaintiffs by April 7, 2026, to potentially receive compensation without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that during the class period, PomDoctor was involved in a fraudulent stock promotion scheme that misled investors through social media misinformation and insider trading, which inflated stock prices and misrepresented the company's operations.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, recovering over $438 million for investors in 2019 alone, highlighting its strong track record in this legal domain.
- Investor Guidance: Investors are advised to carefully select legal counsel, with Rosen Law Firm recommending attorneys with proven success in class actions to ensure effective representation in the litigation process.
See More
Reminder for PomDoctor Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased PomDoctor Ltd. (NASDAQ:POM) securities between October 9 and December 11, 2025, to apply as lead plaintiffs by April 7, 2026, or risk losing the opportunity to represent other investors.
- Fee Arrangement: Investors joining the PomDoctor class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages broader participation in the lawsuit.
- Lawsuit Background: The lawsuit alleges that PomDoctor was involved in a fraudulent stock promotion scheme during the class period, with insiders using offshore accounts to dump shares, misleading investors and impacting the company's stock price performance.
- Law Firm's Strength: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, demonstrating its expertise and success rate, which investors should consider when selecting legal counsel.
See More
